Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116120 | 0.98 | SMN1; SMN2 (0.44) | SMN1; SMN2GAALMNACYP2C9ALDH1A1 | |
| SCHEMBL19465036 | 0.79 | TDP1 (0.50) | ALDH1A1POLBHPGD | |
| SCHEMBL22962053 | 0.77 | CA2 (0.45) | ALDH1A1POLBHPGD | |
| SCHEMBL13884525 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2GAALMNACYP2C9ALDH1A1 | |
| SCHEMBL8649731 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAALDH1A1KMT2ARAB9A | |
| SCHEMBL19677922 | 0.77 | POLB (0.44) | SMN1; SMN2GAALMNAALDH1A1KMT2A | |
| SCHEMBL10783460 | 0.76 | ALDH1A1 (0.53) | SMN1; SMN2GAALMNACYP2C9ALDH1A1 | |
| SCHEMBL8024247 | 0.76 | ALDH1A1 (0.61) | GAALMNAALDH1A1KMT2APOLB | |
| SCHEMBL4261207 | 0.76 | ALDH1A1 (0.61) | GAALMNAALDH1A1KMT2APOLB | |
| SCHEMBL4840666 | 0.76 | ALDH1A1 (0.61) | GAALMNAALDH1A1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | SMN1; SMN2 4421/4885GAA 3255/4885LMNA 2924/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | SMN1; SMN2 4127/4885GAA 3610/4885LMNA 3678/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | SMN1; SMN2 4679/4885GAA 3321/4885LMNA 3245/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SMN1; SMN2 4701/4885GAA 3321/4885LMNA 3308/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SMN1; SMN2 4701/4885GAA 3321/4885LMNA 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.